TY - JOUR
T1 - The spectrum of pyruvate dehydrogenase complex deficiency
T2 - Clinical, biochemical and genetic features in 371 patients
AU - Patel, Kavi P.
AU - O'Brien, Thomas W.
AU - Subramony, Sankarasubramon H.
AU - Shuster, Jonathan
AU - Stacpoole, Peter W.
N1 - Funding Information:
This work was supported by NIH grants R34HD065991-01, UL1RR025208 and U54RR025208-01 and by the University of Florida's Clinical and Translational Science Institute . We thank Ms. Kathryn St. Croix for editorial assistance.
PY - 2012/1
Y1 - 2012/1
N2 - Context: Pyruvate dehydrogenase complex (PDC) deficiency is a genetic mitochondrial disorder commonly associated with lactic acidosis, progressive neurological and neuromuscular degeneration and, usually, death during childhood. There has been no recent comprehensive analysis of the natural history and clinical course of this disease. Objective: We reviewed 371 cases of PDC deficiency, published between 1970 and 2010, that involved defects in subunits E1, and E1, and components E1, E2, E3 and the E3 binding protein of the complex. Data sources and extraction: English language peer-reviewed publications were identified, primarily by using PubMed and Google Scholar search engines. Results: Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency. Structural brain abnormalities frequently included ventriculomegaly, dysgenesis of the corpus callosum and neuroimaging findings typical of Leigh syndrome. Neither gender nor any clinical or neuroimaging feature differentiated the various biochemical etiologies of the disease. Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting. Survival bore no relationship to the underlying biochemical or genetic abnormality or to gender. Conclusions: Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤. 20.
AB - Context: Pyruvate dehydrogenase complex (PDC) deficiency is a genetic mitochondrial disorder commonly associated with lactic acidosis, progressive neurological and neuromuscular degeneration and, usually, death during childhood. There has been no recent comprehensive analysis of the natural history and clinical course of this disease. Objective: We reviewed 371 cases of PDC deficiency, published between 1970 and 2010, that involved defects in subunits E1, and E1, and components E1, E2, E3 and the E3 binding protein of the complex. Data sources and extraction: English language peer-reviewed publications were identified, primarily by using PubMed and Google Scholar search engines. Results: Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency. Structural brain abnormalities frequently included ventriculomegaly, dysgenesis of the corpus callosum and neuroimaging findings typical of Leigh syndrome. Neither gender nor any clinical or neuroimaging feature differentiated the various biochemical etiologies of the disease. Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting. Survival bore no relationship to the underlying biochemical or genetic abnormality or to gender. Conclusions: Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤. 20.
KW - Congenital lactic acidosis
KW - Dichloroacetate
KW - Ketogenic diet
KW - Neuroimaging
KW - Pyruvate dehydrogenase complex
KW - Thiamine
UR - http://www.scopus.com/inward/record.url?scp=84855353341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855353341&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2011.09.032
DO - 10.1016/j.ymgme.2011.09.032
M3 - Review article
C2 - 22079328
AN - SCOPUS:84855353341
SN - 1096-7192
VL - 105
SP - 34
EP - 43
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 1
ER -